SARS-CoV Infection
174
4
7
91
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
16 trials with published results (9%)
Research Maturity
91 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.5%
13 terminated out of 174 trials
87.5%
+1.0% vs benchmark
14%
25 trials in Phase 3/4
18%
16 of 91 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 91 completed trials
Clinical Trials (174)
COVID-19 Contact Study by Antigen Detection Test
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
COVID-19 Vaccine Response in Chronic Respiratory Conditions
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome
Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Antibody Detection of Vaccine-Induced Secretory Effects
KIDney Injury in Times of COVID-19 (KIDCOV)
COVID-19 Persistence in Stool
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
SARS-CoV-2 Human Challenge Characterisation Study
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept
Imaging Immune Activation in COVID-19
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)